Read on to discover more about some of our exciting and innovative investees, who are undertaking ground-breaking research and development across the life science, medtech and AI technology sectors.
TusPark Cambridge Science Park project is the newest addition to the TUS Holdings’ unique “Science Park + Incubation + Investment” development model. With an investment of £200M from TusPark, the landmark joint venture with Trinity College at the University of Cambridge was established to develop and operate the brand new TusPark Cambridge Science Park. TusPark’s investment is the largest ever investment in the history of Cambridge Science Park. It also becomes a member of TUS Holdings’ global network, which has the world’s largest science park network with over 300 incubators, science parks and science cities.
Cambridge Innovation Capital (CIC) backs world-leading life sciences and technology companies with an affiliation to Cambridge, Europe’s leading capital for innovation. As a preferred investor for the University of Cambridge, the CIC has unparalleled access to investment opportunities in the ecosystem.
Since its inception in 2013, the CIC has raised £500 million to invest in disruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health and genomics/proteomics. (30 portfolio companies, including CMR Surgical, Bicycle Therapeutics, Congenica, PragmatIC, Riverlane).
Biosceptre is a biopharmaceutical company developing targeted therapeutics and immune-oncology products against non-functional P2X7 (nfP2X7), a cancer target that has been shown to be present on the majority of cancers. Its goal is to bring novel therapeutics to patients suffering from a wide range of malignancies.
Diagnostics for the Real World (DRW), established in 2003 as a spin-out from the Diagnostics Development Unit at the University of Cambridge, is dedicated to tackling some of the world’s most serious infectious diseases using breakthrough point-of-care (POC) diagnostics. Its mission is to serve the large, unmet need in resource-limited settings and provide innovative, high-performance, easy-to-use diagnostics under “real world” conditions to support clinical services for people in real need. DRW technologies also meet the rapidly growing needs in the developed world where the advantages of POC testing are spurring its popularity.
ThingTrax was founded in 2015 to help manufacturers transform the way their labour, processes and machinery connect. Dedicated to building the autonomous factory of the future, using cloud computing, Internet of Things and artificial intelligence, its mission is to turn the 80% of unconnected factories worldwide into smart manufacturing hubs; connecting machines, workers and robotics to improve efficiency, increase worker safety, reduce costs and drive productivity.